Teija-Kaisa 2012 [68]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Townley 2015 [69]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Vardanian 2011 [70]

2

2

2

1

0

2

2

2

13/16

Retrospective cohort

Vieira 2016 [71]

2

2

2

2

2

2

2

1

2

2

2

1

22/24

RCT

Winocour 2015 [72]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Yang 2017 [73]

2

2

2

2

0

0

2

2

12/16

Retrospective cohort

Yetim 2010 [74]

2

2

2

1

0

2

2

1

2

2

2

1

19/24

RCT

Qualitative Analysis

Chattha 2017 [75]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Cooney 2016 [76]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Cordeiro 2016 [77]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

de Oliveira 2014 [78]

2

2

2

2

2

2

2

2

2

2

2

1

23/24

Non-randomised controlled trial

Dieterich 2013 [79]

2

2

2

2

0

2

2

2

14/16

Prospective cohort

Gil-Londoño 2017 [80]

2

2

2

2

0

2

2

2

14/16

Prospective cohort

Giordano 2013 [81]

2

2

2

1

0

2

2

1

12/16

Retrospective cohort

Golfam 2011 [82]

2

2

2

2

2

2

2

1

2

2

0

1

20/24

RCT

Gülçelık 2017 [83]

2

2

2

2

0

0

2

1

11/16

Retrospective

cohort

Mittal 2017 [84]

2

2

2

1

0

2

2

1

2

2

2

1

19/24

RCT

Parikh 2016 [85]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Pellino 2014 [86]

2

2

2

2

0

2

2

1

2

2

2

1

20/24

RCT

Pettke 2016 [87]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Santosa 2016 [88]

2

2

2

2

0

2

2

2

14/16

Retrospective cohort

Williams 2011 [89]

2

2

2

2

2

2

2

2

2

2

2

2

24/24

RCT